Literature DB >> 19364287

Adalimumab treatment of life-threatening tuberculosis.

Robert S Wallis1, Cloete van Vuuren, Samantha Potgieter.   

Abstract

Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19364287     DOI： 10.1086/598504

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  40 in total

1.  A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Authors:  Denise C Hsu; Kimberly F Faldetta; Luxin Pei; Virginia Sheikh; Netanya S Utay; Gregg Roby; Adam Rupert; Anthony S Fauci; Irini Sereti
Journal:  Clin Infect Dis       Date:  2015-09-22       Impact factor: 9.079

Review 2.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

Review 3.  New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.

Authors:  Santiago Caño-Muñiz; Richard Anthony; Stefan Niemann; Jan-Willem C Alffenaar
Journal:  Clin Microbiol Rev       Date:  2017-11-29       Impact factor: 26.132

4.  Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Authors:  Steffen Hess; Toni Hospach; Robert Nossal; Günther Dannecker; Klaus Magdorf; Frank Uhlemann
Journal:  Eur J Pediatr       Date:  2011-05-31       Impact factor: 3.183

Review 5.  Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none.

Authors:  Daniel L Barber; Bruno B Andrade; Irini Sereti; Alan Sher
Journal:  Nat Rev Microbiol       Date:  2012-01-09       Impact factor: 60.633

Review 6.  Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.

Authors:  Jacqueline M Achkar; Elizabeth R Jenny-Avital
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

Review 7.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

8.  The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

Authors:  Bintou A Ahidjo; Mariama C Maiga; Elizabeth A Ihms; Mamoudou Maiga; Alvaro A Ordonez; Laurene S Cheung; Sarah Beck; Bruno B Andrade; Sanjay Jain; William R Bishai
Journal:  JCI Insight       Date:  2016-09-08

Review 9.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

10.  Independent association of younger age with hemoptysis in adults with pulmonary tuberculosis.

Authors:  J M Achkar; G Joseph
Journal:  Int J Tuberc Lung Dis       Date:  2012-05-07       Impact factor: 2.373
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.